NCT06669572View on ClinicalTrials.gov

Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

January 13, 2026

Primary Completion Date

March 26, 2029

Study Completion Date

March 26, 2029

Conditions
Carcinoma, Squamous CellAnorectal Cancer
Interventions
DRUG

Pembrolizumab

"Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.~Pembrolizumab will be given for a maximum of 2 years (total 35 cycles) with dosing every 3 weeks."

DRUG

Lenvatinib

Lenvatinib will be taken once daily, with or without food, at the same time each day.

Trial Locations (1)

60637

o University of Chicago Medicine Comprehensive Cancer Center, Chicago

All Listed Sponsors
lead

University of Chicago

OTHER